Arthritis News and Research

Latest Arthritis News and Research

End-stage ankle arthritis: New treatment options for baby boomers

There's good news for active older adults who are plagued with arthritic ankles. Surgeons presenting today at the American College of Foot and Ankle Surgeons' Annual Scientific Conference in Las Vegas are re-thinking treatment approaches for end-stage ankle arthritis.

25 Feb 2010

SSRIs exhibit anti-inflammatory effects and may provide drug development opportunities for RA

A new study found that fluoxetine (Prozac-) and citalopram (Celexa-) treatment significantly inhibited disease progression of collagen-induced arthritis (CIA) in mice. Research led by Sandra Sacre, Ph.D. from the Brighton and Sussex Medical School (BSMS) in the UK studied the anti-arthritic potential of these drugs, known as selective serotonin reuptake inhibitors (SSRIs), most commonly used to treat depression.

25 Feb 2010

Osiris Therapeutics' net income for fourth-quarter 2009 increases to $15.7M

Osiris Therapeutics, Inc., the leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, cardiovascular and orthopedic areas, announced today its results for the fourth quarter and year ended December 31, 2009.

24 Feb 2010

Over-produced PKC-iota oncogene linked to poor pancreatic cancer patient survival

Researchers at the Mayo Clinic campus in Florida have found that PKC-iota (PKC), an oncogene important in colon and lung cancers, is over-produced in pancreatic cancer and is linked to poor patient survival. They also found that genetically inhibiting PKC in laboratory animals led to a significant decrease in pancreatic tumor growth and spread.

24 Feb 2010

Prochymal achieves response rate of 63% when used as rescue therapy in children suffering from GvHD

Osiris Therapeutics, Inc. today reported that a new study shows Prochymal achieved an overall response rate of 63% when used as a rescue therapy in children suffering from severe treatment resistant graft vs. host disease (GvHD).

24 Feb 2010

Phase III trial results of Osiris Therapeutics' Prochymal for GvHD to be presented at BMT Tandem Meeting

Osiris Therapeutics, Inc. today announced that results from the Phase III trial evaluating Prochymal for the treatment of steroid-refractory acute graft vs. host disease (GvHD) will be presented by Paul Martin, M.D., of the Fred Hutchinson Cancer Research Center and Paul Szabolcs, M.D., of Duke University Medical Center at the 2010 BMT Tandem Meeting. The meeting is being held February 24-28 in Orlando, Florida.

24 Feb 2010

Idera Pharmaceuticals presents IMO-3100 TLR antagonist mechanism of action data at Keystone conference

Idera Pharmaceuticals, Inc. today presented data on the mechanism of action of IMO-3100, an antagonist of Toll-like Receptor (TLR) 7 and TLR9, in a preclinical primate model at the Keystone Symposia conference “Tolerance and Autoimmunity” being held February 21-26 in Taos, New Mexico. Idera is developing IMO-3100 for the treatment of autoimmune diseases. The presentation entitled “IMO-3100, a novel antagonist, suppresses TLR7- and TLR9-mediated immune responses in non-human primates” was made by Idera scientists.

24 Feb 2010

Religious belief can reduce depression symptoms

Research suggests that religious belief can help protect against symptoms of depression, but a study at Rush University Medical Center goes one step further.

24 Feb 2010

Researchers receive grant to study how ILD appears in patients with autoimmune diseases

Researchers at the University of Cincinnati Interstitial Lung Disease Center have received a grant from the National Heart, Lung and Blood Institute to study ways ILD first appears in certain patient groups with autoimmune diseases and how to more efficiently diagnose and treat it.

24 Feb 2010

Rising Medicare costs linked to the growth in common costly chronic conditions: Study

Today, two of the nation's leading health and fiscal policy experts discussed how to reign in rising health care costs in Medicare in light of a new Health Affairs study that shows rising Medicare costs in the nation's health care system are linked to the growth in several common costly chronic conditions, such as diabetes, arthritis, hypertension, and kidney disease.

24 Feb 2010

Timely treatment and rehabilitation key to proper healing

Sometimes athletes can be their own worst enemy especially when they continue to play following an injury to a foot or ankle. Surgeons presenting at the Annual Scientific Conference of the American College of Foot and Ankle Surgeons (ACFAS) today are discussing athletic injuries and the importance of proper diagnosis, prompt treatment, and full healing and rehabilitation.

23 Feb 2010

Lexicon Pharmaceuticals reports positive results from Phase 2 clinical trials for IBS and type 2 diabetes

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three months and year ended December 31, 2009.

23 Feb 2010

NCC, Pfizer provide over 10M units of ReFacto Antihemophilic Factor to underserved hemophilia patients

The National Cancer Coalition (NCC) is pleased to announce its recent collaboration with Pfizer, Inc to provide hemophilia medicines to underserved patients in the developing world. To date, NCC has received more than 10 million international units of ReFacto® Antihemophilic Factor (Recombinant), a therapy used for the treatment and prevention of bleeding in people with hemophilia A, to assist patients who otherwise would have little opportunity for adequate treatment. The value of this donation is more than $13 million, and it will help many hundreds of hemophilia patients around the world.

23 Feb 2010

Study shows CEL-2000 vaccine blocks RA progression in mice

CEL-SCI Corporation and their scientific collaborators announced today that the Company's CEL-2000 vaccine demonstrated that it is able to block the progression of rheumatoid arthritis (RA) in a mouse model.

23 Feb 2010

CINJ researchers test malaria drug for colorectal cancer treatment

While new cases of colorectal cancer continue to decline in the United States, it remains the third leading cause of cancer death in the nation, according to the American Cancer Society. That is why researchers at The Cancer Institute of New Jersey are looking to add a drug known for fighting malaria to traditional chemotherapy for colorectal cancer to see if treatment can be made more effective for patients.

23 Feb 2010

Research Roundup: Financing boomers' care; California's budget cuts; Racial disparities in surgical outcomes

Health Affairs: Chronic Conditions Account For Rise In Medicare Spending From 1987 To 2006 - "Medicare beneficiaries' medical needs, and where beneficiaries undergo treatment, have changed dramatically over the past two decades." For example, the authors write, "heart disease ranked first among the top-ten conditions in terms of attributable share of growth from 1987 to 1997, accounting for nearly 14 percent of the increase in Medicare spending."

20 Feb 2010

Amgen's Prolia Complete Response submission: FDA classifies and sets PDUFA date

Amgen Inc. today announced that the U.S. Food and Drug Administration (FDA) has evaluated the content of the Company's Complete Response submission for Prolia™ (denosumab) in the treatment of postmenopausal osteoporosis and classified it as a Class 2 resubmission. With the Class 2 designation, the FDA set a corresponding Prescription Drug User Fee Act (PDUFA) action date of July 25, 2010.

20 Feb 2010

SSHS selects Eclipsys’ Sunrise Enterprise suite of solutions for integrating EHR across multiple care venues

Eclipsys Corporation®, The Outcomes Company®, today announced that Sound Shore Health System (SSHS) will undergo an accelerated activation of Eclipsys’ Sunrise Enterprise™ integrated suite of solutions at both its Sound Shore Medical Center of Westchester (New Rochelle, NY) and Mount Vernon Hospital (Mount Vernon, NY) facilities.

19 Feb 2010

Contrast-enhanced MRI may help physicians differentiate between rheumatoid and psoriatic arthritis

Contrast-enhanced magnetic resonance imaging (MRI) may help physicians differentiate between rheumatoid arthritis and psoriatic arthritis in the hand and wrist enabling more targeted therapies unique to each condition, according to a study in the March issue of the American Journal of Roentgenology. Contrast-enhanced MRI uses contrast media to improve the visibility of internal bodily structures.

19 Feb 2010

FDA approves Rituxan-FC combination therapy for CLL

Genentech, Inc., a wholly owned member of the Roche Group, and Biogen Idec announced today the U.S. Food and Drug Administration (FDA) approved Rituxan® (rituximab) in combination with fludarabine and cyclophosphamide (FC) for people with previously untreated and previously treated CD20-positive chronic lymphocytic leukemia (CLL).

18 Feb 2010

Arthritis News and Research

Latest Arthritis News and Research

End-stage ankle arthritis: New treatment options for baby boomers

SSRIs exhibit anti-inflammatory effects and may provide drug development opportunities for RA

Osiris Therapeutics' net income for fourth-quarter 2009 increases to $15.7M

Over-produced PKC-iota oncogene linked to poor pancreatic cancer patient survival

Prochymal achieves response rate of 63% when used as rescue therapy in children suffering from GvHD

Phase III trial results of Osiris Therapeutics' Prochymal for GvHD to be presented at BMT Tandem Meeting

Idera Pharmaceuticals presents IMO-3100 TLR antagonist mechanism of action data at Keystone conference

Religious belief can reduce depression symptoms

Researchers receive grant to study how ILD appears in patients with autoimmune diseases

Rising Medicare costs linked to the growth in common costly chronic conditions: Study

Timely treatment and rehabilitation key to proper healing

Lexicon Pharmaceuticals reports positive results from Phase 2 clinical trials for IBS and type 2 diabetes

NCC, Pfizer provide over 10M units of ReFacto Antihemophilic Factor to underserved hemophilia patients

Study shows CEL-2000 vaccine blocks RA progression in mice

CINJ researchers test malaria drug for colorectal cancer treatment

Research Roundup: Financing boomers' care; California's budget cuts; Racial disparities in surgical outcomes

Amgen's Prolia Complete Response submission: FDA classifies and sets PDUFA date

SSHS selects Eclipsys’ Sunrise Enterprise suite of solutions for integrating EHR across multiple care venues

Contrast-enhanced MRI may help physicians differentiate between rheumatoid and psoriatic arthritis

FDA approves Rituxan-FC combination therapy for CLL

Industry Focus: Cell & Gene Therapy eBook

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Arthritis News and Research

Latest Arthritis News and Research

Industry Focus: Cell & Gene Therapy eBook

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Newsletters you may be interested in